stockrow
Friday 6 November 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
70.03
1.32
+1.92%
Follow EXEL
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 9 | 7 | 5 | 6 | 4 | 4 | 7 | 7 | 6 |
P/E ratio |
15.17 | 18.50 | 36.63 | 28.60 | 24.87 | 54.24 | 16.62 | 8.55 | 59.25 | 0.00 |
Altman Z-Score |
12.68 | 10.04 | 7.86 | 6.54 | 10.00 | 15.41 | 17.32 | 27.49 | 12.76 | 0.33 |
P/S ratio |
5.13 | 4.45 | 4.16 | 3.25 | 4.01 | 6.27 | 5.51 | 6.86 | 20.37 | 19.28 |
P/FCF ratio |
14.10 | 15.24 | 44.69 | 23.38 | 17.10 | 34.63 | 10.37 | 15.31 | 63.74 | 17.67 |
Altman Z″-Score (non-manufacturers) |
7.69 | 6.99 | 5.76 | 7.65 | 9.94 | 11.11 | 12.24 | 13.73 | (2.89) | (8.78) |
P/Operating CF |
35.69 | 40.20 | 720.21 | 71.12 | 59.68 | 185.83 | 33.74 | 56.02 | 172.79 | 43.36 |
Beneish M-Score |
(2.61) | (2.67) | (2.62) | (2.64) | (2.33) | (2.62) | (3.12) | (0.32) | 0.82 | (0.42) |
P/B ratio |
5.51 | 4.30 | 3.36 | 2.11 | 2.60 | 3.29 | 3.16 | 4.55 | 32.35 | 41.32 |
Price to Tangible BV |
5.67 | 4.43 | 3.46 | 2.16 | 2.68 | 3.41 | 3.29 | 4.79 | 41.66 | 143.96 |
EV/Sales |
4.68 | 3.95 | 3.63 | 2.46 | 3.01 | 5.07 | 4.65 | 6.06 | 19.55 | 17.51 |
EV/EBITDA |
12.06 | 13.53 | 33.78 | 17.79 | 14.36 | 41.98 | 11.92 | 11.67 | 52.94 | 0.00 |
EV/Operating CF |
12.29 | 12.24 | 19.93 | 10.91 | 10.76 | 23.95 | 8.55 | 12.46 | 53.41 | 15.93 |
EV/FCF |
12.87 | 13.52 | 38.99 | 17.65 | 12.81 | 28.01 | 8.76 | 13.53 | 61.16 | 16.05 |
Quick Ratio |
3.32 | 3.41 | 3.13 | 4.70 | 5.18 | 6.68 | 6.80 | 8.12 | 4.08 | 1.71 |
Current Ratio |
3.56 | 3.63 | 3.34 | 4.99 | 5.43 | 7.06 | 7.08 | 8.50 | 4.21 | 1.74 |
Net Debt/EBITDA |
(1.18) | (1.75) | (5.06) | (5.88) | (4.89) | (10.12) | (2.26) | (1.56) | (2.23) | 22.46 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.28% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
Asset Turnover |
0.80 | 0.74 | 0.61 | 0.57 | 0.60 | 0.49 | 0.59 | 0.82 | 0.72 | 0.41 |
Operating CF/Net income |
1.13 | 1.34 | 1.60 | 1.99 | 1.73 | 1.87 | 1.64 | 0.60 | 1.07 | (3.00) |
Capex/Depreciation |
(1.37) | (2.30) | (6.34) | (6.63) | (4.71) | (3.32) | (1.54) | (6.71) | (17.67) | (0.17) |
Interest Coverage |
— | — | — | 6.11 | 35.83 | 5.50 | 13.20 | 33.76 | 19.12 | (0.85) |
| 35.53% | 23.13% | 8.74% | 7.76% | 11.30% | 6.27% | 21.59% | 87.77% | 82.41% | 272.77% | |
| 27.02% | 17.70% | 6.91% | 6.41% | 9.72% | 5.56% | 19.41% | 66.43% | 24.66% | (15.13%) | |
ROIC |
49.46% | 33.35% | 8.42% | 10.67% | 24.10% | 10.23% | 27.70% | 46.17% | 0.00% | 0.00% |
Return on Tangible Assets |
68.85% | 44.06% | 19.74% | 12.97% | 14.43% | 8.55% | 34.99% | 81.91% | 39.00% | (34.71%) |
Average Days of Receivables |
45.14 | 44.67 | 47.35 | 48.66 | 71.90 | 59.46 | 44.91 | 69.58 | 65.50 | 77.11 |
Research and Development Expense of Revenue |
35.56% | 41.98% | 57.05% | 55.36% | 48.34% | 55.48% | 34.82% | 21.35% | 24.79% | 50.13% |
Selling, General and Administrative Expense of Revenue |
22.36% | 22.69% | 29.65% | 28.54% | 27.99% | 29.71% | 23.58% | 24.17% | 35.21% | 60.66% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.10 | 0.11 |
Share Based Compensation of Revenue |
4.87% | 4.33% | 5.81% | 6.68% | 8.35% | 10.64% | 5.85% | 4.76% | 5.29% | 11.97% |
Graham Net Nets |
0.06 | 0.08 | 0.08 | 0.20 | 0.25 | 0.19 | 0.15 | 0.13 | 0.01 | (0.01) |
Graham Number |
22.75 | 17.70 | 10.23 | 9.96 | 10.78 | 7.12 | 11.53 | 14.96 | 3.40 | 0.00 |
Earnings Yield |
6.59% | 5.41% | 2.73% | 3.50% | 4.02% | 1.84% | 6.02% | 11.69% | 1.69% | (2.38%) |
Free Cash Flow Yield |
7.09% | 6.56% | 2.24% | 4.28% | 5.85% | 2.89% | 9.64% | 6.53% | 1.57% | 5.66% |
Revenue per Share |
8.54 | 7.48 | 5.75 | 5.01 | 4.56 | 3.20 | 3.20 | 2.87 | 1.54 | 0.76 |
Operating CF per Share |
3.26 | 2.41 | 1.05 | 1.13 | 1.27 | 0.68 | 1.74 | 1.40 | 0.56 | 0.84 |
Capex per Share |
(0.15) | (0.23) | (0.51) | (0.43) | (0.20) | (0.10) | (0.04) | (0.11) | (0.07) | (0.01) |
Free Cash Flow per Share |
3.11 | 2.19 | 0.54 | 0.70 | 1.07 | 0.58 | 1.70 | 1.28 | 0.49 | 0.83 |
Cash per Share |
3.90 | 3.83 | 3.13 | 4.07 | 4.66 | 3.91 | 2.82 | 2.33 | 1.32 | 1.68 |
Shareholders Equity per Share |
7.96 | 7.74 | 7.12 | 7.74 | 7.02 | 6.10 | 5.57 | 4.32 | 0.97 | 0.36 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.96 | 7.74 | 7.12 | 7.74 | 7.02 | 6.10 | 5.57 | 4.32 | 0.97 | 0.36 |
Free Cash Flow |
844.34 | 633.79 | 170.36 | 224.16 | 336.58 | 178.64 | 514.12 | 382.73 | 144.63 | 208.80 |
Working Capital |
1,037.65 | 1,063.81 | 923.68 | 1,294.40 | 1,497.16 | 1,240.74 | 868.44 | 791.54 | 369.70 | 200.22 |
Capital Expenditures |
(39.93) | (66.18) | (162.97) | (138.46) | (64.22) | (30.34) | (12.83) | (32.99) | (20.98) | (1.61) |
Net Current Asset Value |
760.19 | 764.09 | 639.51 | 1,035.70 | 1,429.12 | 1,187.18 | 811.49 | 762.18 | 114.54 | (37.42) |
EV/EBIT |
12.46 | 14.18 | 38.87 | 19.63 | 15.04 | 45.47 | 12.19 | 11.80 | 53.31 | 0.00 |
Capex to Sales |
0.02 | 0.03 | 0.09 | 0.09 | 0.04 | 0.03 | 0.01 | 0.04 | 0.05 | 0.01 |
Price to Operating Income |
13.65 | 15.97 | 44.55 | 26.01 | 20.08 | 56.21 | 14.43 | 13.35 | 55.56 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.24 | 0.20 | 0.19 | 0.13 | 0.14 | 0.17 | 0.10 | 0.05 | 4.56 |
Cash ROIC |
26.22% | 18.89% | 5.23% | 5.90% | 9.15% | 5.79% | 20.26% | 19.32% | 21.02% | 41.01% |
Accounts Receivable Turnover |
8.40 | 8.63 | 8.09 | 6.48 | 6.47 | 7.06 | 6.87 | 7.00 | 7.44 | 8.39 |
Accounts Payable Turnover |
2.47 | 2.12 | 2.18 | 2.03 | 2.21 | 2.06 | 2.94 | 2.57 | 0.31 | 0.14 |
Inventory Turnover |
3.80 | 3.84 | 2.87 | 1.91 | 2.18 | 2.14 | 2.91 | 3.19 | 3.01 | 2.20 |
Average Days of Payables |
129.19 | 182.90 | 169.89 | 205.90 | 167.46 | 237.81 | 127.72 | 151.01 | 231.97 | 4,822.38 |
Days of Inventory on Hand |
94.57 | 107.22 | 87.16 | 209.88 | 189.79 | 211.05 | 142.11 | 136.29 | 161.28 | 185.95 |
Average Receivables |
276.18 | 251.42 | 226.10 | 248.72 | 221.76 | 139.97 | 140.92 | 121.98 | 60.82 | 22.81 |
Average Payables |
33.91 | 35.98 | 33.22 | 28.46 | 23.95 | 17.61 | 11.24 | 10.24 | 48.07 | 46.48 |
Average Inventory |
22.04 | 19.86 | 25.31 | 30.40 | 24.23 | 16.93 | 11.36 | 8.25 | 5.00 | 2.98 |
Average Assets |
2,896.06 | 2,945.02 | 3,006.92 | 2,843.86 | 2,376.79 | 2,011.50 | 1,653.98 | 1,038.79 | 625.52 | 464.04 |
Average Common Equity |
2,202.76 | 2,254.06 | 2,376.17 | 2,349.52 | 2,044.86 | 1,782.54 | 1,486.71 | 786.21 | 187.14 | (25.74) |
Columns are period end dates · fundamentals updated 5 Nov 2026